AB0723 Technical aids agreed among specialists for the management of comorbidity in patients with axial spondyloarthritis: the gecoax project. (15th June 2017)

• Record Type: Journal Article
• Authors: González, C; Curbelo, R; Torre-Alonso, JC; Collantes, E; Castañeda, S; Hernández, MV; Urruticoechea-Arana, A; Nieto, JC; García, J; Abad, MΆ; Ramírez, J; Suárez, C; Dalmau, R; Martín-Arranz, MD; Leόn, L; Hermosa, JC; Obaya, JC; Otόn, T; Carmona, L
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 1307
• Page End: 1307
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.4795
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The management of comorbidity in patients with axial spondyloarthritis (Ax-SpA) needs improvement; the implementation of clinical practice guidelines is still deficient and heterogeneous. Objectives: To prioritise comorbidities in Ax-SpA and to elaborate practical aids for their identification and follow-up. Methods: A multidisciplinary panel [10 rheumatologists (6 experts in Ax-SpA), 2 family doctors, 1 internist, 1 cardiologist, 1 gastroenterologist, 1 psychologist and 3 methodologists] prioritised, in a discussion group, a list of comorbidities based on frequency and impact. Each comorbidity was discussed largely and systematic reviews were performed to support or discard items. In a second meeting, items to be included were presented, discussed, and those with lower priority disregarded. Results: The panel produced a checklist for health professionals and another for patients. Each item is supported by arguments and references. Table 1 shows, schematically, the items included in the checklists. Conclusions: These checklists are intended to facilitate the systematic evaluation of co-morbidity associated with Ax-SpA, thus allowing an earlier detection and better control and management of these patients by the rheumatologist. Acknowledgements: This project was funded by Merck Sharp & Dohme Spain. Merck Sharp & Dohme had no influence on either the development of the project or the final content of the abstract. Disclosure of Interest: None declared